Get it on Google Play

Rigel to present R289 and Tavalisse data at ASH meeting

November 4, 2026 9:15 AM EST Send to a Friend
Rigel Pharmaceuticals (Nasdaq: RIGL) will present data from its ongoing Phase 1b clinical study of R289, an investigational dual IRAK1/4 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login